We came across a bullish thesis on Compass Therapeutics, Inc. on r/stocks by Cute_Confidence6033. In this article, we will summarize the bulls’ thesis on CMPX. Compass Therapeutics, Inc.’s share was trading at $5.70 as of January 16th.
Compass Therapeutics (CMPX) is a clinical-stage oncology company with a focused pipeline targeting large, underserved cancer markets, and its current valuation appears disconnected from the scale of its opportunity. With a share price around $6 and a market capitalization of approximately $1.2 billion, the company holds a strong cash position of $209 million against a historically manageable annual cash burn of $30–50 million, providing runway through multiple critical data readouts.
Ownership quality is a key differentiator, with roughly 65% institutional ownership led by specialist healthcare investors such as Tang Capital, OrbiMed, Suvretta, Vivo, BVF, and Patient Square, alongside 10% insider ownership and a long-tenured board that signals strategic continuity. The core value driver is CTX-009 (tovecimig), with a Phase 3 program in biliary tract cancer targeting an estimated $1.5 billion peak sales opportunity and a Phase 2 colorectal cancer program with $2 billion-plus potential, significantly expanding the addressable patient population.
Additional upside comes from CTX-471 in solid tumors, CTX-8371 in PD-1–resistant tumors, and early-stage PD-1 x VEGF programs, bringing total pipeline potential above $4.5 billion. Recent developments reinforce confidence, including the hiring of Arjun Prasad, a recognized commercial leader in cholangiocarcinoma, encouraging signals from the Phase 3 COMPANION-002 trial showing fewer deaths than projected, and the appointment of a former Sanofi/Genzyme executive to senior leadership.
With major catalysts ahead, including Phase 3 BTC data in March 2026, ASCO presentation mid-2026, and potential BLA filing in late 2026, Compass Therapeutics offers a highly asymmetric, catalyst-driven upside, with bullish scenarios implying substantial rerating if clinical success is confirmed.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the commercial ramp of Casgevy, strong net cash position, and upside from its broader gene-editing pipeline. CRSP’s stock price has appreciated by approximately 30.60% since our coverage as the thesis played out. Cute_Confidence6033 shares a similar thesis but emphasizes on late-stage, catalyst-driven oncology upside at Compass Therapeutics with multiple binary readouts ahead.
